145 related articles for article (PubMed ID: 30208333)
1. Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics.
Everett KL; Kraman M; Wollerton FPG; Zimarino C; Kmiecik K; Gaspar M; Pechouckova S; Allen NL; Doody JF; Tuna M
Methods; 2019 Feb; 154():60-69. PubMed ID: 30208333
[TBL] [Abstract][Full Text] [Related]
2. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
[TBL] [Abstract][Full Text] [Related]
3. Engineered IgG1-Fc--one fragment to bind them all.
Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
[TBL] [Abstract][Full Text] [Related]
4. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
[TBL] [Abstract][Full Text] [Related]
6. Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054.
Cebada J; Flores A; Bandala C; Lizaliturri-Flores I; Villa-Ruano N; Perez-Santos M
Expert Opin Ther Pat; 2020 Jul; 30(7):487-494. PubMed ID: 32397849
[TBL] [Abstract][Full Text] [Related]
7. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
8. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
9. Bispecific mAb
Stadlbauer K; Andorfer P; Stadlmayr G; Rüker F; Wozniak-Knopp G
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563599
[TBL] [Abstract][Full Text] [Related]
10. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
[TBL] [Abstract][Full Text] [Related]
11. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
12. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
[TBL] [Abstract][Full Text] [Related]
13. Two-faced Fcab prevents polymerization with VEGF and reveals thermodynamics and the 2.15 Å crystal structure of the complex.
Lobner E; Humm AS; Mlynek G; Kubinger K; Kitzmüller M; Traxlmayr MW; Djinović-Carugo K; Obinger C
MAbs; 2017 Oct; 9(7):1088-1104. PubMed ID: 28816592
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes.
Huard B; Tournier M; Hercend T; Triebel F; Faure F
Eur J Immunol; 1994 Dec; 24(12):3216-21. PubMed ID: 7805750
[TBL] [Abstract][Full Text] [Related]
15. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
[TBL] [Abstract][Full Text] [Related]
16. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.
Skegro D; Stutz C; Ollier R; Svensson E; Wassmann P; Bourquin F; Monney T; Gn S; Blein S
J Biol Chem; 2017 Jun; 292(23):9745-9759. PubMed ID: 28450393
[TBL] [Abstract][Full Text] [Related]
18. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
[TBL] [Abstract][Full Text] [Related]
20. Selection of High-Affinity Heterodimeric Antigen-Binding Fc Fragments from a Large Yeast Display Library.
Benedetti F; Stadlmayr G; Stadlbauer K; Rüker F; Wozniak-Knopp G
Methods Mol Biol; 2023; 2681():131-159. PubMed ID: 37405647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
